Healthcare Providers and Services
Company Overview of University Health Network
University Health Network provides patient care, education, and research services in Canada. The company operates four hospital sites, including Princess Margaret Cancer Centre, Toronto General Hospital, Toronto Western Hospital, and Toronto Rehabilitation Institute. Its Princess Margaret Cancer Centre offers diagnostic, treatment, and follow-up care services in medical, surgical, and radiation oncology areas with 12 site groups and 26 specialty clinics. The company’s Toronto General Hospital provides services in the areas of cardiac care, organ transplants, and the treatment of complex patient needs. Its Toronto Western Hospital offers services in the areas of neuroscience, musculoskeletal ...
R. Fraser Elliott Building
190 Elizabeth Street
Toronto, ON M5G 2C4
Key Executives for University Health Network
Chief Executive Officer and President
Medical Director of the Medicine and Community Health Program
Director of Technology Development and Commercialization
Compensation as of Fiscal Year 2015.
University Health Network Key Developments
Sernova Corp. Signs License Agreement with University Health Network
Sep 10 15
Sernova Corp. has signed a license agreement with the University Health Network to gain exclusive worldwide rights to certain patent-pending technologies developed by UHN researchers. These technologies relate to the development of stem cells into glucose-responsive therapeutic cells for the treatment of patients with insulin-dependent diabetes.
Hamad Medical Corporation Announces Working Relationship with University Health Network-Princess Margaret Cancer Centre
Jun 24 15
Hamad Medical Corporation (HMC) announced a new working relationship with Canadian cancer specialists, the University Health Network-Princess Margaret Cancer Centre (UHN/PM) Toronto.
Generex Biotechnology Corp. Collaborates with University Health Network for Buccal Insulin Project
Sep 22 14
Generex Biotechnology Corporation announced that it has entered into a collaboration with University Health Network (UHN) pursuant to which UHN's Centre for Molecular Design and Preformulations (CMDP) will spearhead the Company's buccal insulin refinement project. The goal of the project is to increase the insulin bioavailability of Generex Oral-lyn(TM), the Company's proprietary buccal insulin spray product, thereby reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes. This research will ensure the product is more attractive to patients and prospective commercialization partners.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries